Eagle Pharmaceuticals Inc
Eagle Pharmaceuticals, Inc., a pharmaceutical company, focuses on developing and commercializing product candidates to treat diseases of the central nervous system or metabolic critical care, and oncology in the United States. The company offers Ryanodex for malignant hyperthermia; and Belrapzo and Bendeka for chronic lymphocytic leukemia and indolent B-cell non-Hodgkin's lymphoma. Its product ca… Read more
Market Cap & Net Worth: Eagle Pharmaceuticals Inc (EGRX)
Eagle Pharmaceuticals Inc (PINK:EGRX) has a market capitalization of $24.43 Million ($24.43 Million) as of March 19, 2026. Listed on the PINK stock exchange, this USA-based company holds position #26447 globally and #8947 in its home market, demonstrating a 88.50% increase in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Eagle Pharmaceuticals Inc's stock price $1.89 by its total outstanding shares 12958200 (12.96 Million).
Eagle Pharmaceuticals Inc Market Cap History: 2015 to 2025
Eagle Pharmaceuticals Inc's market capitalization history from 2015 to 2025. Data shows change from $1.15 Billion to $24.43 Million (-31.71% CAGR).
Eagle Pharmaceuticals Inc Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Eagle Pharmaceuticals Inc's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.
Latest Price to Sales (P/S) Ratio
1.20x
Eagle Pharmaceuticals Inc's market cap is 1.20 times its annual revenue
1.02x
Higher than industry averageLatest Price to Earnings (P/E) Ratio
10.63x
Eagle Pharmaceuticals Inc's market cap is 10.63 times its annual earnings
10.35x
Higher than industry averageWhat These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2015 | $1.15 Billion | $66.23 Million | $2.57 Million | 17.35x | 446.91x |
| 2016 | $1.03 Billion | $189.48 Million | $81.45 Million | 5.43x | 12.62x |
| 2017 | $692.23 Million | $236.71 Million | $51.94 Million | 2.92x | 13.33x |
| 2018 | $522.09 Million | $213.31 Million | $31.90 Million | 2.45x | 16.36x |
| 2019 | $778.53 Million | $195.89 Million | $14.31 Million | 3.97x | 54.39x |
| 2020 | $603.46 Million | $187.80 Million | $11.99 Million | 3.21x | 50.33x |
| 2021 | $659.83 Million | $171.55 Million | -$8.63 Million | 3.85x | N/A |
| 2022 | $378.77 Million | $316.61 Million | $35.64 Million | 1.20x | 10.63x |
Competitor Companies of EGRX by Market Capitalization
Companies near Eagle Pharmaceuticals Inc in the global market cap rankings as of March 19, 2026.
Key companies related to Eagle Pharmaceuticals Inc by market ranking:
- Zoetis Inc (NYSE:ZTS): Ranked #410 globally with a market cap of $53.52 Billion USD.
- Haleon plc (NYSE:HLN): Ranked #434 globally with a market cap of $49.87 Billion USD.
- Takeda Pharmaceutical Co. Ltd. (PINK:TKPHF): Ranked #457 globally with a market cap of $47.47 Billion USD.
- Jiangsu Hengrui Medicine Co Ltd (SHG:600276): Ranked #721 globally with a market cap of $28.19 Billion USD ( CN¥206.84 Billion CNY).
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #410 | Zoetis Inc | NYSE:ZTS | $53.52 Billion | $121.68 |
| #434 | Haleon plc | NYSE:HLN | $49.87 Billion | $10.60 |
| #457 | Takeda Pharmaceutical Co. Ltd. | PINK:TKPHF | $47.47 Billion | $30.07 |
| #721 | Jiangsu Hengrui Medicine Co Ltd | SHG:600276 | $28.19 Billion | CN¥55.11 |
Eagle Pharmaceuticals Inc Historical Marketcap From 2015 to 2025
Between 2015 and today, Eagle Pharmaceuticals Inc's market cap moved from $1.15 Billion to $ 24.43 Million, with a yearly change of -31.71%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2025 | $24.43 Million | +165.49% |
| 2024 | $9.20 Million | -86.42% |
| 2023 | $67.77 Million | -82.11% |
| 2022 | $378.77 Million | -42.60% |
| 2021 | $659.83 Million | +9.34% |
| 2020 | $603.46 Million | -22.49% |
| 2019 | $778.53 Million | +49.12% |
| 2018 | $522.09 Million | -24.58% |
| 2017 | $692.23 Million | -32.67% |
| 2016 | $1.03 Billion | -10.52% |
| 2015 | $1.15 Billion | -- |
End of Day Market Cap According to Different Sources
On Mar 18th, 2026 the market cap of Eagle Pharmaceuticals Inc was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $24.43 Million USD |
| MoneyControl | $24.43 Million USD |
| MarketWatch | $24.43 Million USD |
| marketcap.company | $24.43 Million USD |
| Reuters | $24.43 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.